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ABSTRACT  
   
 The effects of iron and chromium blood concentrations have been linked to blood 
glucose control in diabetics.  It is suggested that iron causes oxidative stress in the beta 
cells of the pancreas and adipocytes creating insulin insufficiency and resistance.  
Chromium is believed to increase the action of insulin through its biologically active 
molecule chromodulin.  Both of these mechanisms are not clear.  This 20 week case 
study tests the feasibility of combining iron depletion therapy followed by chromium 
supplementation to improve insulin sensitivity.  This single case study followed a 
protocol of two blood donations separated by eight weeks followed by chromium 
supplementation of 250 µg of chromium picolinate once a day four weeks after the 
second blood donation.  Fasting blood draws were taken at baseline, post blood draws 
and pre and post chromium supplementation.  Results were not promising for the first 
hypothesis of lowering HbA1c, but the results were promising for the second hypothesis 
of improving insulin sensitivity by lowering the HOMA score.   
  ii 
DEDICATION  
   
This is dedicated to my family, my husband Damian and my children Adara, Marcus, 
Jason, and Chanel, who fill my life with joy and the power to succeed.  I am grateful that 
God has blessed me with the Love and Support of you all. 
I am also grateful to my brothers William and Robert who showed strength, courage, and 
support as we sent out loving mother and grandmother to heaven.  We Love and 
Remember you Debra E. Johnson and Carmen A. Henry. 
  iii 
ACKNOWLEDGMENTS  
   
I would like to thank God for being a constant source in my life and aligning me 
with Arizona State University and its outstanding faculty and staff.  I would like to 
especially thank Dr. Carol Johnston for guiding me and supporting me in my endeavors 
at ASU and my future endeavors as a health care provider.  
Dr. Sandra Mayol-Kreiser and Dr. Christy Lespron have been a tremendous 
support in my learning experience at ASU and a valued part of my committee, thank you.  
Their commitment to excellence and dedication to help students succeed is unsurpassed.  
Dr. Mayol-Kreiser takes students to the next level with her simulation labs and vast 
knowledge while Dr. Lespron takes complex biochemical reactions and simplifies them 
while elevating the level of enjoyment with her kindness.  Thank you to all of my friends 
and classmates that have shared laughs and other expressions during this journey.  I am 
grateful and honored to share this experience together.  
 
 
 
 
 
 
 
 
  iv 
TABLE OF CONTENTS  
          Page 
LIST OF TABLES ................................................................................................................... vi  
LIST OF FIGURES ............................................................................................................... vii  
CHAPTER 
1     INTRODUCTION .................  .................................................................................... 1  
Overview .................................................................................................... 1  
The Study Purpose ..................................................................................... 3 
Research Aim and Hypothesis ................................................................... 4 
Definition of Terms .................................................................................... 4 
Delimitations .............................................................................................. 5 
Limitations.................................................................................................. 5  
2     REVIEW OF LITERATURE  .................................................................................... 7  
Overview .................................................................................................... 7 
Type 2 Diabetes Mellitus Overview .......................................................... 8 
Type 2 Diabetes and Iron ......................................................................... 14 
Iron and the Pancreas ............................................................................... 20 
Iron Depletion Therapy ............................................................................ 21 
Type 2 Diabetes and Chromium .............................................................. 23 
Chromium Supplementation .................................................................... 25 
3     METHODS ......................  ........................................................................................ 28 
Participants ............................................................................................... 28 
Study Design ............................................................................................ 29 
  v 
CHAPTER           Page 
Measurements .......................................................................................... 31 
4     RESULTS ......................  .......................................................................................... 32 
5     DISCUSSION ...................  ....................................................................................... 40 
6     CONCLUSION ...................  .................................................................................... 46 
REFERENCES.......  .............................................................................................................. 47 
APPENDIX 
A      INSTITUTIONAL REVIEW BOARD APPROVAL  ........................................... 52  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  vi 
LIST OF TABLES 
Table Page 
1.       Lab Results by Visit  ............................................................................................. 38 
2.       Daily Blood Glucose Levels from Glucometer  ................................................... 39 
 
  vii 
LIST OF FIGURES 
Figure Page 
1.       Diagnostic Criteria for Diabetes Mellitus  ...................................................... 9 
2.       Estimated Average Blood Glucose in Realtion to HbA1c ............................ 10 
3.       The Transportation of Iron  ............................................................................ 15 
4.       Siderocalins Process used to Mediate Bacterial Growth  ............................. 17 
5.       Molecules used to Sequester Iron in Various Species .................................. 18 
6.       Proposed Mechanism of Iron Accumulation ................................................. 21 
7.       C-Lobe and N-Lobe of Human Serum Transferrin ....................................... 24 
8.       Graph of Daily Blood Glucose with Confounding Factors ........................... 38 
9.       Line Graph Comparison of Lab Values ......................................................... 39 
 
  
 
 
  1 
CHAPTER 1 
INTRODUCTION 
Overview 
Type 2 diabetes produces significant health impacts on a primary and secondary 
level with an economic burden of approximately $245 billion for diagnosed cases of 
diabetes; which does not account for the burden of the undiagnosed (American Diabetes 
Association, April 2013).  The Primary condition of uncontrolled blood glucose control 
leads to secondary illnesses such as neuropathy, blindness, and amputations which 
significantly decreases quality of life (McCormack & Grant, 2013) (American Diabetes 
Association,).  Understanding the ability to control blood glucose concentrations through 
improving insulin secretion and sensitivity is critical for improving health outcomes in 
individuals with type 2 diabetes.  Current literature recommends increasing physical 
activity and reducing body weight which is important in improving blood glucose 
concentrations (McCormack & Grant, 2013) (American Diabetes Association,2013).  
This study explored the impact of initial iron depletion therapy through blood donation 
combined with subsequent chromium supplementation on insulin secretion, insulin 
sensitivity, and daily blood glucose control.  Blood donation has been shown to reduce 
iron concentrations and improve insulin production through reducing pancreatic 
inflammation (Hansen, Moen, & Mandrup-Poulsen, 2014).  Chromium is associated with 
improved glucose uptake into cells through chromodulin (Quarles Jr, Marcus, & 
Brumaghim, 2011).  Chromodulin is an intercellular protein that binds chromium III in 
cells and increases tyrosine kinase activity to amplify the strength of insulin receptors to 
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bind insulin (Quarles Jr et al., 2011).  Increasing the strength of insulin binding improves 
the expression of GLUT 4 to the cells plasma membrane.  GLUT 4 is an insulin 
dependent transporter that brings glucose into muscle and adipose cells for energy 
production (Quarles Jr et al., 2011). 
Improving the amount of chromium crossing the plasma membrane is significant 
in improving the activity of chromodulin.  Chromium is a dietary essential found in 
Brewer's yeast, lobster tail, mushrooms, chicken, shrimp, and black pepper (R. A. 
Anderson, 1981).  The American diet typically contains about 5 to 125 µg of chromium 
(R. A. Anderson, 1981).  Chromium interacts with other dietary components affecting its 
bioavailability.  Iron in particular impacts chromium status.  High dietary iron can reduce 
chromium absorption (Quarles Jr et al., 2011).  Moreover, high iron status is believed to 
reduce chromium transport to cells (Quarles Jr et al., 2011).  Transferrin is the protein 
that transports chromium into the cell which is also the primary carrier of iron (III).  
Reducing iron status through blood donations will lower ferritin concentrations and 
increase affinity for chromium to bind the C-lobe of transferrin (Quarles Jr et al., 2011) 
(Peffer et al., 2013).  Hence, theoretically, reducing iron status via blood donations in 
individuals with type 2 diabetes and high iron status would enhance chromium delivery 
to cells, an effect that would be amplified by chromium supplementation. 
This research sought to expand upon the understanding of treatments to improve glucose 
control in individuals with diabetes using blood donation with chromium 
supplementation.  Current research correlates increased ferritin concentrations with 
elevated HbA1c concentrations (Batchuluun et al., 2014)and a reduction in HbA1c and 
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ferritin with whole blood donation (Hansen et al., 2014) (Peffer et al., 2013).  
Chromodulin, the biologically active from of chromium, research related to treatment 
improvements for type 2 diabetics necessitates further exploration of the benefit in human 
supplementation due to the lack of knowledge depth (Chen, 2011) .  Additionally, to our 
knowledge there is no research in the literature examining these combined methods of 
chromium supplementation and iron depletion through blood donation.  From our review 
many chromium studies fail to explore the role of iron in relation to chromium.  Men tend 
to have higher transferrin saturation and higher iron stores versus women and will 
compose the study sample (McLaren, Li, Gordeuk, Hasselblad, & McLaren, 2001).  
Successful outcomes will include an increase in serum chromium concentrations, lower 
HbA1c, improved HOMA, and daily fasting blood glucose management within healthy 
limits for type 2 diabetes.  Increased chromium concentrations will indicate blood 
donations improved chromium (III) loading on transferrin for purposes of this study.  The 
need to further understand the implications of iron status and diabetes is imperative to 
further understanding of diabetes management (Hansen et al., 2014). 
The Study Purpose 
 This case study explored the relationship of blood donation and chromium 
supplementation with improved diabetes management.  This 20 week study included 2 
blood donations separated by 8 weeks to decrease ferritin concentrations to improve 
HbA1c levels and increase affinity for chromium III to bind transferrin.  Furthermore, 
supplementation of chromium as 250 µg /d of chromium picolinate was investigated to 
measure the effects on insulin sensitivity via chromodulin.  The Participant tracked his 
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daily waking blood glucose and self-report taking chromium picolonate orally on a 
compliance calendar to confirm program consistency. 
 It is our belief that the combination of iron depletion through blood donations 
followed by chromium supplementation will show improvement in blood glucose 
markers.  This case study was intended to be a feasibility exploration to support larger 
studies. 
Research Aim and Hypothesis 
H1: Phlebotomy and chromium treatments will improve glucose management as 
indicated by daily fasting glucose measurement and HbA1c levels in individuals with 
T2D. 
H2: Phlebotomy and chromium treatments will improve insulin sensitivity as measured 
by HOMA in individuals with T2D. 
Definition of Terms  
Chromium Picolinate: A form of biologically active chromium salt that is used as an oral 
supplement. 
Chromodulin:  An amino acid residue made of carboxylate, cysteine, glycine, aspartate 
and glutamate which bind up to four chromium ions. It is also known as a low molecular 
weight substance capable of binding chromium (Chen, 2011) (Vincent, 2001).  
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HbA1c: Measures the amount of glucose attached to red blood cells. This gives a 
measure of how well blood glucose has been managed over an eight to twelve week 
period. This is also called glycated hemoglobin (Ezenwaka, Seales, Surujlal, & Mathura, 
2009). 
HOMA: Homeostasis model assessment-estimated insulin resistance (HOMA-IR), this is 
used to measure insulin resistance in diabetes research (Qu, Li, Rentfro, Fisher-Hoch, & 
McCormick, 2011). 
Delimitations 
 The participants that met the inclusion criterion had been diagnosed by a Medical 
Doctor (by self-report) and displayed an elevated ferritin concentration and transferrin 
saturation based on sex as men tend towards higher levels (McLaren et al., 2001).  Blood 
values set were acceptable values that indicated satisfactory management of type 2 
diabetes mellitus which allowed for reasonable deductions that treatment protocol would 
produce results (American Diabetes Association, ).  Excluded participants included those 
with low iron status, current chromium supplementation, and elevated inflammation 
markers.  This population is comfortable with daily finger pricks which elevates 
compliance and participation for study length.  This study lasted for 20 weeks. 
Limitations 
 The participant is a Type 2 diabetics and his illness is subject to change in 
severity which presented the need for adjustment in medications not to include 
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administering of insulin.  Change of lifestyle had potential to affect blood glucose 
concentrations and HbA1c (McCormack & Grant, 2013) (American Diabetes 
Association,).  Oral ingestion of supplements was self-reported and relied upon accuracy 
and consistency of participant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  7 
CHAPTER 2 
REVIEW OF LITERATURE 
Overview 
Type 2 diabetes mellitus is a complex disease that has shown to be improved with 
alternative treatments and lifestyle changes (American Diabetes Association, 2014).  
Understanding multiple approaches to minimize cost of treatment and management, and  
progression of this disease is critical due to the many other illnesses and injuries that type 
2 diabetes mellitus causes (McCormack & Grant, 2013) (Pscherer, Dippel, Lauterbach, & 
Kostev, 2012) (Viitasalo et al., 2012) (Kannan, 2012).  Iron overload and chromium 
deficiency has shown to be associated with type 2 diabetes mellitus (Bao, Rong, Rong, & 
Liu, 2012; Basaki, Saeb, Nazifi, & Shamsaei, 2012).  The question this research sought to 
answer is how iron depletion combined with chromium supplementation affects blood 
glucose control.  The effects of combining these therapies to improve blood glucose 
concentrations in type 2 diabetics are unknown.  These treatments offer a cost effective 
method that may be added to lifestyle changes with the possibility of high compliance. 
The goal of this literature review was to understand current knowledge relating to 
the impact of type 2 diabetes mellitus, the effects of iron overload on the organ systems 
in type 2 diabetes, specifically impairment in the endocrine function of the pancreas, the 
effects of chromium in the diabetic condition and, finally, the benefits of iron depletion 
with chromium supplementation on improving healthy blood glucose concentrations. 
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Type 2 Diabetes Mellitus Overview 
 The pathogenesis of type 2 diabetes mellitus is different than other forms of 
diabetes in that most affected have healthy functioning of blood glucose control until 
something goes wrong (American Diabetes Association, April 2013).  The progression of 
this disease is a combination of decreased insulin secretion from the beta cells of the 
pancreas and insulin resistance which decreases the cells ability to bring glucose in for 
energy production.  The beta cells of the pancreas begin to die or fail; the insulin 
receptors on the cells begin to lose sensitivity and control, and if the patient is obese 
controls of hunger are out of balance; which results in difficulty in managing compliance 
to diet regulations to control glucose (American Diabetes Association, April 2013).  This 
disease is devastating on a personal, community and global level.  This discussion will 
cover the impact this disease has on the health of individuals and the financial burden of 
society.  This illness is a worldwide problem that is expanding rapidly (Weber, 2010).  A 
continual development of methods to manage healthy blood glucose concentration in type 
2 diabetics in a cost effective manner is vital (American Diabetes Association, 2014). 
The American Diabetes Association recognizes diabetes as an HbA1c level 
greater than 6.5%.  This measure gives a look at blood glucose levels over a 60-90 day 
period according to the ADA (American Diabetes Association, 2014).  Individuals with 
HbA1c of 5.7-6.4% are considered levels that are a high risk for developing diabetes and 
considered a pre diabetic level (American Diabetes Association, 2014).  
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 Fasting plasma glucose is another diagnostic measure that is taken after fasting for 
eight hours.  When the plasma glucose level is greater than 126 mg/dl an individual is 
considered to have diabetes (American Diabetes Association, 2014).  Normal fasting 
plasma glucose levels are less than 100 mg/dl with a pre diabetic state with levels 
between 100-125 mg/dl.  An oral glucose tolerance test is a diagnostic test that looks at 
how an individual processes glucose (American Diabetes Association, 2014).  Glucose 
levels are tested before and two hours after drinking a glucose rich beverage of 
approximately 75 grams of glucose, this amount can be less for shorter testing time 
frames and more for longer time frames (American Diabetes Association, 2014).  Blood 
glucose levels higher than 200 mg/dl after 2 hours meet diagnostic criteria for a diagnosis 
of diabetes (American Diabetes Association, 2014).  Normal levels are less than 140 
mg/dl after 2 hours and pre diabetic levels are 140-199 mg/dl after 2 hours (American 
Diabetes Association, 2014).  A random test of blood glucose known as a causal test 
resulting in a reading greater than 200 mg/dl are also considered a diagnostic criterion for 
diabetes (American Diabetes Association, 2014).  The ADA provides a simple graphic to 
help with making understanding and comparing these values easy (Figure 1). 
 
Figure 1.  Diagnostic criteria for diabetes mellitus from the American Diabetes 
Association (American Diabetes Association, 2014). 
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The measure of HbA1c can be confusing as it estimates the amount of glucose on 
a hemoglobin molecule based on the levels of glucose in the blood for the previous two to 
three months (American Diabetes Association, 2014).  It can sometimes be confusing to 
understand what the changes mean.  When the percentage of glycation on a hemoglobin 
molecule increases by 1% there is an approximate increase in blood glucose 
concentrations in a rough range of 14-16 mg/dl.  This range is estimated from a chart 
provided in an article on the ADA’s website by Erika Gebel PhD (Figure 2) 
(Gebel,2011).  The ADA highlighted the benefit of this measure as being able to diagnose 
diabetes without needing to complete and oral glucose tolerance test (American Diabetes 
Association, 2014).   
 
Figure 2.  This chart provides an estimate of the average blood glucose concentrations in 
relation to a HbA1c percentage (American Diabetes Association, 2014 & Gebel 2011).   
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Impact 
Type 2 diabetes mellitus has a devastating impact of the health of individuals due 
to the additional disorders that arise.  A 2014 article by The American Diabetes 
Association “Standards of Medical Care in Diabetes-2014” discusses cardiovascular 
disease as the number one cause of morbidity and mortality in diabetics (American 
Diabetes Association, 2014).  The devastation to individual health is not limited to 
cardiovascular disease; it encompasses damage throughout the body to include 
amputations, renal, hepatic, and vision dysfunction.  This list is not exhaustive but 
addresses the most devastating complications associated with type 2 diabetes mellitus.  
Lower limb amputation is a key insult that can be reduce with improved blood glucose 
concentrations which minimize lesions of the feet and lower legs (Gregg et al., 2014; 
Mundet et al., 2012; Pscherer et al., 2012).  The impacts on hearing and oral health are 
additional areas of health comorbidities that are receiving attention in the literature 
(American Diabetes Association, 2014; Gregg et al., 2014; Kannan, 2012).  These 
complications also lead to psychological complications due to lifestyle changes, financial 
burden, and reduction in quality of life from health disparities (American Diabetes 
Association, April 2013). 
 The financial burden of caring for type 2 diabetics is a global problem that is 
mounting (Weber, 2010).  In the U.S. alone the direct medical costs reached $176 billion 
with an additional estimated $69 billion in lost productivity (American Diabetes 
Association, April 2013).  One of the most eye opening revelations in the literature is the 
disparity in mortality rates across economic levels.  Lower income individuals have a 
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higher mortality rate from diabetes; but, this disparity decreased in individuals as they 
age once their incomes is subsidized by social security, Medicare benefits, and assistance 
with medicine when patients are over 65 based on a study by Lipscombe and colleagues 
that looked at the mortality rate in Canadian diabetics over an eleven year time frame 
(Lipscombe et al., 2010).  This helps significantly mediate complication and illness due 
to the development of comorbidities when medication compliance is hindered due to 
affordability.  When Lipscombe and colleagues looked at the mortality rate in Canadian 
diabetics over an eleven year time frame it was shown a higher mortality in the younger 
diabetic population even though their medical care cost is covered, yet medications may 
not be (Lipscombe et al., 2010).  It is speculated that this problem is elevated in the US 
for people who do not have health care insurance complicated by extensive medications 
and associated cost of other health complications (American Diabetes Association, April 
2013).  
 
Pathogenesis 
 Type 2 DM results when the pancreas is impaired and no longer produces 
adequate insulin from the beta cells and disturbances in metal concomitant has been 
attributed to assisting in the development and progression of this disease (Khan & Awan, 
2014).  In addition to the beta cells producing lower levels of insulin the insulin receptors 
become weaker and create an insulin resistance (American Diabetes Association, April 
2013).  Disturbances in metal concentrations due to polyuria and renal dysfunction are 
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believed to contribute to the reduced insulin sensitivity in type 2 DM (Gabrielsen et al., 
2012).  A study by J. Scott Gabrielsen and colleagues found a dysfunction in adipocytes 
insulin regulation based on iron overload.  The sensitive balance of all body metals are 
highlighted in an article published by the Journal of Diabetic & Metabolic disorders; this 
article discussed the relationship of elevated iron and insufficient chromium levels in 
exacerbating the pathogenesis of type 2 DM(Khan & Awan, 2014).   
Type 2 Diabetes and Iron 
Iron and Diabetes 
Research has shown that excess iron affects the beta cells of the pancreas thus 
reducing insulin production and contributing to impaired blood glucose 
concentrations(Bao et al., 2012; Batchuluun et al., 2014; Creighton Mitchell & McClain, 
2014; Gupta, Palta, Singh, & Lehl, 2014; Hansen et al., 2014; Kalra, Chawla, & Madhu, 
2013).  It is mentioned in the literature that this association has been realized since 1865 
(Hansen et al., 2014).  There are various treatments for type 2 diabetes mellitus to include 
traditional and alternative approaches in the quest for control of healthy blood glucose 
concentration and minimization of complications (American Diabetes Association, April 
2013).  Several studies have explored iron reduction through chelation and or blood 
donations; this review discusses blood donations to reduce iron concentration (Ikeda, 
2014; Peffer et al., 2013).  Understanding the effectiveness of iron depletion therapy is 
helpful as the association of high iron stores and heme-iron intake have been positively 
associated with Type 2 Diabetes Mellitus (Bao et al., 2012).  
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 Iron is an essential and most prevalent trace mineral in the body; responsible for 
assisting with storing, regulating and transporting oxygen throughout the body, immune 
function, energy production, metabolic processes, and DNA synthesis which is 
responsible for significant bodily processes.  Iron is highly safeguarded when transported 
through the body (Figure 1) due to its ability to cause reactive oxygen species and the use 
of iron by any pathogens present (Creighton Mitchell & McClain, 2014) 
 Sources of dietary iron are found in meats, poultry, and fish and provide mostly 
heme forms of iron, which are absorbed easier than non heme forms from plants and 
dairy (Hansen et al., 2014).  Iron enters the system through the cells of the intestine based 
on the form of iron ingested.  Heme iron enters on the haem carrier protein 1 and the 
oxidized iron is transported on the divalent metal transporter into the intestinal cell 
(Hansen et al., 2014).  Once inside the cell it is stored in the cell as ferritin or transported 
through ferroportin to the bloodstream and delivered to cells on transferrin (Hansen et al., 
2014).  Hepcidin is a regulation protein that is made by the liver and the pancreas, it 
regulates iron uptake by binding to ferroportin and stopping iron from coming in and out 
of the cell (Hansen et al., 2014).  Iron is highly regulated in the body as it is critical in 
oxygen transport, protein synthesis, and other functions.  It is also used by other 
organisms and during times of infection the body works to store iron to minimize use 
from pathogens (Sia, Allred, & Raymond, 2013).  This protective mechanism is believed 
to be the mechanism that creates iron overload in diabetic patients as the cells absorbs 
iron during times of inflammation, which is a common condition in diabetics (Hansen et 
al., 2014). 
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Figure 3.  The transportation of iron (Fe+3 and Fe+2) is highly controlled as shown in 
this diagram (Creighton Mitchell & McClain, 2014). 
 Iron is highly regulated in the body to maintain healthy concentrations, support 
various biochemical reactions, and to ensure it is delivered to the cells that need it for 
proper functioning.  The first regulation point is the absorption of iron in the intestines.  
This is where the form of dietary iron is significant.  Heme-iron is absorbed at a 
significantly higher percentage than nonheme-iron and has been noted in studies as a 
contributing factor to type 2 diabetes mellitus as it relates to excess accumulation (Bao et 
al., 2012).  This higher absorption is an issue because once iron is in the body there are 
few ways the body excretes the iron.  This may be one reason why iron overload 
increases with age and as people age the risk for type 2 diabetes increases (Hansen et al., 
2014).  In a cross sectional observational study by Gupta and colleagues, they showed no 
correlation in elevated serum ferritin concentrations of an Indian population with type 2 
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diabetics noting the predominance of a vegetarian diet (Gupta et al., 2014).  This study 
reported a lack of evidence to support the correlation of high serum ferritin and type 2 
diabetes mellitus in their population which incidentally supports the previous study 
discussed that connected high heme intake with high iron stores.  It is important to note 
that because their population is primarily vegetarian the predominant source of dietary 
iron is non-heme form thus decreasing bioavailability.  In addition, a plant based diet may 
have other benefits that obscure the effects of the decreased bioavailability of the iron.  
The plant based diet may mediate pancreatic inflammation due to the high level of 
antioxidants. 
 The necessity of iron is highly regarded for all living organisms.  Pathogenic 
bacteria in a human body produce siderophores to scavenge for iron for their own use 
which is why a type chaperone system of iron exists in humans as another immune 
mechanism to minimize the proliferation of pathogens especially of a bacterial nature.  
The process that the human body uses intercepts the iron that the siderophores scavenge 
by binding the siderophore with the iron and releasing it back to a molecule called a 
Siderocalin (Scn) which frees the iron to be recycled to for use of the human or mammal 
as this is a mammalian mechanism (figure 2) (Sia et al., 2013) .  There are several forms 
of molecules used in the process of iron sequestering and transport (figure 3) (Sia et al., 
2013). 
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Figure 4.  This shows the process that Siderocalins use to mediate bacterial growth by 
minimizing the use of iron by bacterial pathogens (Sia et al., 2013). 
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Figure 5.  This shows the various types of molecules used to sequester iron in various 
species (Sia et al., 2013). 
Once in the blood iron is carefully transported to cells where needed to assist in 
critical life supporting functions.  In cases of diabetes mellitus type 1 and 2 there is an 
increase in inflammation throughout the body (American Diabetes Association, 1978).  
This is important because ferritin is increased to bind iron and minimize its circulation 
when inflammation is present.  It is believed this mechanism is used to minimize 
pathogens from using the iron for their own life supporting functions.  This is a 
mechanism performed by numerous cells in the body.  This discussion will focus on the 
cells of the pancreas and the pathogenesis of type 2 diabetes mellitus which is believed to 
be complicated by excess systemic and cellular iron concentrations.   
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Iron and the Pancreas  
The beta cells of the pancreas are responsible for the secretion of insulin; and iron 
is a key essential mineral needed for this process.  However when iron is in excess the 
beta cells of the pancreas are destroyed by mechanisms that are speculated upon but not 
fully understood.  In a review by Hansen et.al., two mechanisms are proposed that 
warrant discussion and consideration.   
First, apoptosis of the beta cells of the pancreas based on the labile iron pool, free 
ferrous iron, is believed to be a cause (Hansen et al., 2014).  When inflammation is 
experienced cytokine activity increases and signals cell death through the up regulation of 
siderophore binding proteins, Siderocalins, which sequester excess iron from pathogens 
(Sia et al., 2013).  The uptake of extra iron in the cells increases the amount of reactive 
oxygen species (ROS) created from Fenton reactions with other molecules.  The hydroxyl 
is the specific ROS that is toxic to the beta cells of the pancreas.  When these toxic 
molecules accumulate the beta cells self-destruct, which in turn reduced the amount of 
insulin secreted thus diminishing blood glucose control.  This mechanism is highly 
simplified as it is a theory and warrants further investigation. 
Ferroptosis is the second mechanism of beta cell death in the pancreas that is 
explored.  This mechanism is of great interest as it is directly related to excess cellular 
iron.  It is believed that the ROS, hydroxyl, along with cysteine enters the cell causing an 
iron dependent cell death.  It is not clear if this form of cell death is related to some beta 
cells or is just part of the process to induce cell death from iron overload.  
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Iron Depletion Therapy 
Initial search of iron reduction and type 2 diabetes mellitus returns thousands of 
articles on various topics.  The clear assumption is that iron and diabetes is heavily 
discussed and researched.  The literature shows a benefit in reducing iron though iron 
chelation or blood donations but much more research needs to be done to support this 
treatment (Peffer et al., 2013). 
A robust study by Peffer and colleagues showed significant reduction in ferritin 
and hepcidin concentrations with blood donation.  Ferritin is the storage form of iron and 
hepcidin regulates iron balance therefore these markers are important measures for iron 
depletion (Peffer et al., 2013).  Although this study was looking at decrease in 
atherosclerosis it showed a decrease of iron markers with whole blood donations.  The 
measures of 152 men and 117 women were reviewed based on the number of lifetime 
whole blood donations, resulting in reduced ferritin and hepcidin concentrations.  A key 
point was frequent blood donations improved markers more than less frequent whole 
blood donations.  Whole blood donation was defined as any blood donation greater than 
100mL. 
Mensud Hatunic and colleagues studied the effects of iron depletion through 
blood removal on 11 subjects with hereditary hemochromatosis (HH), 7 with impaired 
glucose tolerance and 4 with type 2 diabetes.  These subjects received regular blood 
removal as treatment for their HH which consists of 450 mL of blood removed to yield 
roughly 250 mg of iron from the blood; the goal is to reduce ferritin levels to 50 µg/L or 
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reduce % saturation to less than 50 %(Hatunic, Finucane, Norris, Pacini, & Nolan, 2010).  
Two weeks after the treatment researches concluded that small improvements in impaired 
glucose tolerance were achieved (Hatunic et al., 2010). 
Researchers of an epidemiological study concluded that more research needs to be 
done to include iron depletion therapy to further enhance knowledge of the mechanism of 
iron related metabolic disorders to include diabetes (Basuli, Stevens, Torti, & Torti, 
2014).  Debargha Basulu and colleagues propose abnormal insulin sensitivity and 
production due to accumulation of iron which causes oxidative damage in liver, skeletal 
muscle, pancreas and fat cells as illustrated (figure 6 ) in their article.(Basuli et al., 2014).  
Figure 6.  This illustration shows the potential mechanism of iron accumulation and 
effect on blood glucose control.(Basuli et al., 2014).. 
It is clear that iron is a critical element in the pathology of type 2 diabetes 
mellitus.  This mineral as well as the other molecules within the human body do not exist 
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alone, but react with each other and affect their efficiency.  A major mineral in this 
research is chromium which iron has an effect on.   
Type 2 Diabetes and Chromium 
 Chromium is a molecule that has been researched and understood to help 
with macronutrient metabolism and subsequently improving glucose control by 
improving glucose uptake into cells through chromodulin (Quarles Jr et al., 2011) .  
Chromodulin is an intercellular protein that binds chromium III in cells and increases 
tyrosine kinase activity to amplify the strength of insulin receptors to bind insulin 
(Quarles Jr et al., 2011) (Chen, 2011).  Increasing the strength of insulin binding 
improves the expression of GLUT 4 to the cells plasma membrane.  GLUT 4 is an insulin 
dependent transporter that brings glucose into muscle and adipose cells for energy 
production (Quarles Jr et al., 2011) (Chen, 2011). 
Iron and chromium use one of the same transporters to enter the cell; human 
serum transferrin (Tf) (R. A. Anderson, 1981).  This protein has two lobes that are 
comparable.  These lobes are identified as a C-lobe and an N-Lobe with the C-lobe being 
the preferential binding site for chromium (Figure 1).  This is where the exploration of 
iron depletion therapy arises.  The C-lobe is also the preferential binding site for iron 
where it binds first and has a 20 times stronger bond than when it bonds to the N-lobe.  In 
addition, as iron binds the affinity for chromium decreases which may create an inability 
for adequate chromium levels to enter the cell (Quarles Jr et al., 2011).  Quarles Jr. and 
colleagues studied the competitive binding of various minerals to include chromium at 
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various iron concentrations.  Their research suggests as suspected binding of chromium 
to Tf was reduced by half when iron was present in excess.  This is a key point in 
understanding why some studies do not show an improvement with chromium 
supplementation due to the lack of attention given to iron concentrations.  In addition, 
when chromium concentrations were increased iron loaded about six percent less, 
suggesting a potential side benefit of reducing iron uptake into cells with chromium 
supplementation (Quarles Jr et al., 2011).  A study by Ather Ali and colleagues reject the 
theory that chromium supplementation improves insulin resistance.  However, this study 
did not measure chromium concentrations and could not determine absorption of 
supplementation which they mentioned as a major study limitation (Ali et al., 2010).  A 
major limitation not declared is the importance of assessing iron levels as this is a major 
competitor for transport into the cell.  Further support for future studies to include a 
combination protocol of iron depletion through blood donation followed by chromium 
supplementation. 
A meta-analysis by Christopher H. Baily rejects the use of chromium 
supplementation to improve fasting glucose levels.  Again attention to iron levels are not 
addressed which would improve the overall evaluation of the effectiveness of chromium 
supplementation (Bailey, 2014).  This analysis concludes that chromium supplementation 
does not benefit subjects who are not chromium deficient while noting a standard for 
determining deficiency has not been established.  This increases the need for chromium 
studies to include chromium measures at baseline, throughout the study, and include iron 
markers. 
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Further research to understanding the relationship of iron and chromium binding 
this transporter would benefit future studies that combine the methods of iron depletion 
and chromium supplementation as the mechanisms are not fully understood. 
 
Figure 7.  This shows the C-Lobe and the N-Lobe of human serum transferrin that binds 
minerals for uptake into the cell.  The C-lobe shows the affinity for iron and chromium 
binding (Quarles Jr et al., 2011). 
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Chromium Supplementation 
Research Overview 
 An initial search of “The effect of chromium supplementation on blood glucose 
control in individuals with type 2 diabetes” yielded approximately 32 articles in a 
PubMed search database.  Several related to animal studies or did not meet point of 
interest.  Review of several studies found a positive correlation with chromium 
supplementation to improve blood glucose concentrations in individuals with type 2 
diabetes.  A common understanding is supplementation helps to improve blood glucose 
concentrations when chromium status is low yet attention to iron concentrations in 
relation to chromium status is lacking.  In addition this review of the literature found 
evidence of improvement with supplementation above and below the recommended 
intake (R. Anderson et al., 1997). 
 Anderson and colleagues conducted a randomized trial of 180 participants divided 
into three groups; group one was given a placebo, Group two was given chromium 
picolinate two times per day at a dosage of 1.92 mu mol (100 mu g) Cr and group 3 was 
treated with 9.6 mu mol (500 mu g) Cr two times per day.  The participants were 
instructed not to modify their lifestyle in any other way.   The group with the higher dose 
saw improvement in HbA1c after two months and the lower dose group saw 
improvement within four months (R. Anderson et al., 1997). 
 A double blind cross over trial by Suhad M.A.Bahijri  and Asaad M. B. Mufti 
looked at seventy eight participants over twenty four weeks.  This study showed that 
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chromium supplementation improves blood glucose concentrations in individuals with 
type 2 diabetes mellitus.  The use of Torula yeast, CrCl3, brewer’s yeast, and placebo 
supplements were given to all participants with a 8 week cross over method.  The brewers 
yeast elicited the best glucose control response (Bahijri & Mufti, 2002).  In addition, this 
study showed that urine chromium levels are a good indicator of status after a two hour 
glucose load test (Bahijri & Mufti, 2002). 
 Chromium Homeostasis was studied by Morris and colleagues, in individuals 
with type 2 diabetes mellitus.  This controlled trial looked at chromium levels in 93 
individuals with type 2 diabetes mellitus in comparison to 33 individuals without.  The 
results showed a significant difference in the individuals with type 2 diabetes mellitus.  
They showed up to a thirty percent lower concentration of chromium versus the healthy 
participants.  The levels were measured in both blood and urine.  An interesting finding 
was in individuals that had been diagnosed over 2 years; the relationship of decreased 
plasma glucose levels with higher chromium serum concentrations decreased in this 
population.  This may suggest that the benefits of chromium may be decreased in 
populations that have had poor chromium status with Type 2 Diabetes Mellitus long term.  
This indicates a possible benefit to treating individuals with chromium to prevent the 
onset of type 2 diabetes mellitus and for individuals who have been newly diagnosed. 
 A study by Jaroslav Racek and colleagues showed a significant reduction in 
fasting plasma glucose, and HbA1c after supplementing eleven participants with 100 
micrograms of chromium enriched yeast for two weeks followed by an increased dose of 
200 micrograms for six weeks (Racek et al., 2013).  The participants were then taken off 
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the supplementation for a six week washout period which raised their previously lowered 
fasting plasma glucose, and HbA1c concentrations (Racek et al., 2013).  This study was 
limited by the low number of participants as noted by the researchers. 
 Although no guidelines are clear for chromium deficiency a study by Giovanni 
Forte and colleagues showed a difference in chromium concentrations in males with and 
without type 2 DM.  This study looked at the metal concentrations in diabetic and non-
diabetic subjects.  They found that there is roughly a difference of .14 ng/ml in chromium 
concentrations with diabetics having the deficit.  Chromium is a trace mineral and it is 
reasonable to suggest small increases in chromium concentrations may help manage 
blood glucose levels.  This study concluded that supplementation of chromium may be 
useful for blood glucose control.  
 The literature shows several examples of improvement of blood glucose control 
with chromium supplementation although the mechanism is not fully understood 
(Trumbo & Ellwood, 2006).  Further understanding of the mechanism of chromium is not 
provided; however, this investigation adds to the body of knowledge and sets precedence 
for further testing to include evaluation of iron concentrations in relation to chromium 
supplementation. 
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CHAPTER 3 
METHODS 
Participants  
Participants were recruited through list serve, advertisements at local places of 
worship and health organizations that serve diabetic populations.  Participants interested 
in study participation were invited to complete an online survey via survey monkey.  
Upon identifying initial suitability, applicants were to be invited to the downtown ASU 
campus to further establish fit based on inclusion and exclusion criteria from blood draws 
and health questionnaires. 
  This investigation was a case study of a single participant to establish an initial 
understanding of this treatment.  Participants recruited were men aged 30-70 years old 
with a Type 2 Diabetes Mellitus diagnosis from a Medical Doctor greater than 12 months 
with satisfactory management defined as HbA1c >6.2 or <7.5.  The gender specificity 
was because men tend to have higher ferritin concentrations and higher transferrin 
saturation (McLaren et al., 2001).  Additional inclusion criterion included medication 
stability for at least 90 days, willingness and ability to donate blood twice separated by 
eight weeks, no blood donations for the past 12 months, willingness to supply 4 fasting 
blood samples and record daily fasting glucose concentrations, and free of kidney and 
liver disease.  Eligible participant did not regularly supplement chromium and/or iron.  
 Exclusion criterion included hematocrit <44%, hemoglobin <15g/100mL, ferritin 
< 200 µg /L because this study explored the effects of lowering iron stores participants 
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must have had iron markers that indicated elevated ferritin and blood measures associated 
with iron status.  Additionally hsCRP was to be <3 and HOMA-IR score<1 as 
inflammation affects iron status and iron status is highly correlated with diabetes (Hansen 
et al., 2014).  
Participant signed a written consent form upon full disclosure and informed consent.  
This study has been approved by the Arizona State University Institutional Review 
Board. 
Study Design 
This was a 20 week case study.  Potential participants underwent an online pre-
enrollment screening prior to being invited to visit one for further inclusion screening.  
The eligible participants visited the Downtown ASU campus on 5 separate visits to 
complete appropriate paperwork, receive disclosures and collect pertinent data to include 
anthropometric and biochemical measures.  All visits varied in time between 20 -45 
minutes.  
Upon meeting initial screening based on survey monkey the participant came to 
the ABC building nutrition lab at ASU Downtown Phoenix Campus.  Prior to the first 
visit participant had been instructed to fast for 8 hours before coming in the event he 
chose to proceed in study upon receiving full informed consent.  Participant had the free 
and full authority to stop participation at this visit or any subsequent visit.  This first visit 
included the initial informed consent after all questions have been answered, 
anthropometric and biochemical data collected, and delivery of instructions and supplies 
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for daily waking blood sample and testing for exclusion criteria.  Visit 2 was scheduled at 
this initial visit for the following week and final determination for inclusion was 
conveyed to the participant. 
The single participant continued in the study and was instructed to schedule his 
first blood donation at a convenient United Blood Services Center within one week of 
second visit.  Daily waking blood glucose monitoring was to be continued throughout this 
period and duration of study.  Since the participant is a diabetic he was experienced at 
performing this test.  Eight weeks after initial blood donation participant came in for visit 
3 in an 8 hour fasting state and approximately 2 tablespoons of blood was collected and 
the glucometer data was down loaded.  This same process was repeated for visit 4 to 
include another blood donation separated by 8 weeks.  The fourth visit was four weeks 
after second blood donation and at this time participants had been given chromium 
supplements as chromium picolinate (250 µg /d) for four weeks and a compliance sheet 
to track intake.  Visit 5 was four weeks after visit four and the final visit which was the 
study conclusion, included a venous blood draw, glucometer data download, and 
collection of chromium compliance sheets.  Monetary compensation of $10 per visit for a 
total of $50 was provided to participants. 
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Measurements 
 Participants submitted to venous blood draws at visits1,3,4 and 5 to include 1 
finger prick at visit 1.  Venous blood draws were collected by a Registered Nurse or 
trained phlebotomist and blood prick by trained research personnel.  Prior to each venous 
blood draw participants was in an 8 hour fasting state.  Blood analysis was performed at 
the nutrition laboratories at ASU.  Blood concentrations of ferritin were measured by 
Immulite, transferrin by ELISA, Insulin by RIA, A1C by Siemens DCA, glucose and 
CRP by COBAS.  Each sample was fully processed and plasma frozen at -80◦. 
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CHAPTER 4 
RESULTS 
Recruitment for this study started in June 2014 until August 2014 through 
electronic list serves, flier distribution at coffee shops, places of worship, community 
colleges, universities in the greater Phoenix and Scottsdale area, and calls to local 
dietician that serve the diabetic population. Respondents (n=6) completed a questionnaire 
in survey monkey to determine initial qualification. Qualified respondents (n=3) received 
an email confirming acceptability and final inclusion pending blood tests at the ASU 
nutrition labs. Respondent (n=1) to follow up email met inclusion criteria and completed 
a 20 weeks case study commencing on September 26, 2014 and finalizing on February 
13,2015.  
Descriptive Characteristics 
Subject 
One subject was studied to explore the effects of iron depletion through blood 
donations combined with chromium supplementation to improve insulin sensitivity.  35 
year old male diagnosed with type 2 diabetes mellitus September 2013; height 1.75m, 
weight 169.22 kg, BMI 55.2.  Subject has a stable medication history at time of screening 
on September 17th 2014 of Metformin 1000 mg twice a day, Hyzaar (50mg losartan/ 
12.5mg hydrochlorothiazide) once a day since September 2013.  Subject was initially 
excluded due to a false low hematocrit reading based on milking the finger to draw 
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sample which resulted in an excess of serum in the blood sample.  Proper retesting of 
subject resulted in a hematocrit within inclusion criteria of 44.5%.  Subject met inclusion 
criteria and start date adjusted to September 26, 2014.  Prior to baseline blood draws at 
visit 2 patient was prescribed Januvia 50 mg twice a day and discontinued this medication 
prior to week seven due to severe leg pain.  Patient discontinued this medication but 
remained on Metformin and Hyzaar throughout course of study.  During week 13 subject 
was out of all medication due to a prescription error that was corrected on week 14, and 
all medication was resumed with the addition of Glipizide 5 mg once a day for the 
remainder of study period. 
  Health status remained unremarkable until weeks 16-20 where patient acquired a 
common cold that progressed to bronchitis by week 20 when an antibiotic was prescribed 
just prior to final visit 5 on week 20.  The second blood donation was delayed by 1 week 
due to a low hematocrit reading at blood donation center which extended the study to 20 
weeks.  Food diaries and recalls were not used due to the high burden of the study based 
on requirement of daily finger pricks, 6 blood withdrawals to include the 2 blood 
donations, and daily supplement intake and tracking, and 20 week commitment.  Due to 
no food diaries and recalls there are no descriptive analysis of glucose reading based on 
diet.  Compliance on daily finger pricks was 88 % (23/140) and 100% compliance on 
consuming chromium supplement and completing all visits to include 2 blood donations 
at United Blood Services.  Daily finger pricks were performed upon waking which 
included 41% (51/123) of the reading taken after 8am due to the weekend, Thanksgiving 
(US), Christmas (US), and school winter break.  Hypotheses outcomes based on HOMA-
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IR score and HbA1c levels, HOMA-IR score calculated from online calculator and 
HbA1c leels from Sonoran Quest Labs (Maurer, 2015).  
Lab Values and Medications 
Visit 1 
Subject was initially excluded on Visit 1, 9/17/14, based on Hematocrit collection 
error.  Medication, height, and weight collected: height 1.75m, weight 169.22 kg, BMI 
55.2.  Blood draw conducted after error detected and baseline date adjusted to 9/26/14.  
Subject gave list of all medications at this visit which were Metformin 1000 mg twice a 
day, stable since September 2013, Hyzaar (50mg losartan/ 12.5mg hydrochlorothiazide) 
once a day, stable since September 2013. 
 
Visit 2 
This visit confirmed inclusion based on baseline lab data collected at visit 1.  
Baseline data collected 9/26/14 with reported normal levels of chromium at 0.2 mcg/L, 
elevated CRP levels at 10.4 mg/L, normal levels of ferritin at 212 ng/mL, elevated fasting 
insulin levels at 59 uIU/mL, normal levels of iron level 57µg /dL , normal TIBC at 275µg 
/dL , low % Saturation of 21%, elevated HBA1C of 7.5%, elevated estimated average 
glucose level at 169 mg/dL, and normal hematocrit at 44.5%.  The range levels are based 
on the laboratory ranges of Sonoran Quest Laboratories. 
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Visit 3 
Venous blood draw collected on 12/11/14 after first blood donation during week 3 
on 10/16/2013.  Results are relative to baseline levels.  CRP levels increased to 17.2  
mg/L, ferritin levels decreased to 130 ng/mL, fasting insulin levels increased to 81 
uIU/mL , iron levels decreased to 51 µg /dL , TIBC levels increased to 296 µg /dL , % 
Saturation decreased to 17%, HBA1C decreased to 7.3%, estimate average fasting 
glucose levels decreased to 163 mg/dL, and hematocrit decreased to 39.5%.  Chromium 
was excluded from this collection as we are analyzing baseline, pre, and post 
supplementation chromium levels.  Subjects current medications at this visit were 
Metformin 1000 mg twice a day, stable since September 2013, Hyzaar (50mg losartan/ 
12.5mg hydrochlorothiazide) once a day, stable since September 2013, and  
discontinuation of  Januvia during study week 7 (11/13/14).  
 
Visit 4 
Venous blood draw collected 01/16/15 after second blood donation during week 
13 on 12/19/2014.  Results are relative to baseline levels.  Chromium levels remained the 
same at 0.2 mcg/L, CRP levels increased to 14.7 mg/L, ferritin levels decreased to 89 
ng/mL, fasting insulin levels increased to 70 uIU/mL, iron levels remained the same at 51 
µg /dL, TIBC increased to 309 µg /dL, % Saturation decreased to 17%, HBA1C 
increased to 7.6%, estimate avg. glucose increased to 171 mg/dL, and hematocrit 
decreased to 42%.  Subjects current medications at this visit were Metformin 1000 mg 
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twice a day, stable since September 2013, Hyzaar (50mg losartan/ 12.5mg 
hydrochlorothiazide) once a day, stable since September 2013, and started Glipizide 5 mg 
once a day during study week 14 (12/26/14). 
Visit 5 
This is the final visit and end of study.  Venous blood draw collected 02/7/15 after 
both blood donations and 4 weeks of chromium supplementation during weeks 17-20 
from 1/16/15 to 2/7/15.  Results are relative to baseline levels.  Chromium levels 
increased to 0.7 mcg/L, CRP levels increased to 19.1 mg/L, ferritin decreased to 106 
ng/mL, fasting insulin levels decreased to 37 uIU/mL , iron levels decreased to 45 µg /dL 
, TIBC increased to 317 µg /dL , % saturation decreased to 14%, HBA1C increased to 
7.7%, estimated average glucose increased to 174 mg/dL, and hematocrit decreased to 
42.0%.  Subject’s current medications at this visit remain stable since visit 4 with 
Glipizide 5 mg once a day, Metformin 1000 mg twice a day, stable since September 
2013, Hyzaar (50mg losartan/ 12.5mg hydrochlorothiazide) once a day, stable since 
September 2013. 
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Results Charts 
Table 1. Lab Results by visit. Visit 2 did not have blood draws, this visit confirmed 
inclusion and scheduled first blood donation.  
 
Chromium CRP Ferritin 
Fasting 
Insulin Iron TIBC 
% 
Saturation HbA1c 
 
 
 
HOMA 
Score 
Fasting 
Plasma 
Glucose Hematocrit 
  
Visit 
1 0.2 10.4 212 59 57 275 21 7.5 
 
20.4 140* 44.5 
  
Visit 
3 n/a 17.2 130 81 51 296 17 7.3 
 
42.8 214 39.5 
  
Visit 
4 0.2 14.7 89 70 51 309 17 7.6 
 
27.3 158 42.0 
  
Visit 
5 0.7 19.1 106 37 45 317 14 7.7 
 
12.2 136 42.0 
*Based on first fasting plasma glucose reading from participant. 
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Table 2.  Daily blood glucose levels from glucometer.  Missing data are days when 
subject did not take a measure.
 
 
 
Figure 8. Graph of daily blood glucose levels from glucometer with notations of 
confounding factors of study. 
 
Visit 1 Visit 2
1st Blood 
Donation
Week 1 Week 2 Week 3 Week 4 Week 5 Week 6 Week 7 Week 8 Week 9 Week 10
Start 9/26/14 10/3/14 10/10/14 10/17/14 10/24/14 10/31/14 11/7/14 11/14/14 11/21/14 11/28/14
Friday 140 136  154 137 129 126 180 141 151
Saturday 145 132  126  132 140 159 147 127
Sunday 169 141 142 136 146 124 157 239 149 170
Monday 163 204  123  122 146 139 145 160
Tuesday 171 114 125 162 163 128 154 123 159 214
Wednesday 163 135 141 137 148 145 167 141 157 186
Thursday 145 121  129 137 126 179 135 136 160
Avg. mg/dL 157 140 136 138 146 129 153 159 148 167
Visit 3
2nd Blood 
Donation Visit 4 
Start 
Chromium 
Final Visit    
Visit 5 
Week 11 Week 12 Week 13 Week 14 Week 15 Week 16 Week 17 Week 18 Week 19 Week 20
Start 12/5/14 12/12/14 12/19/14 12/26/14 1/2/14 1/9/14 1/16/14 1/23/14 1/30/14 2/7/14
Friday 160 201 237 160 214  158 149 131 138
Saturday 150 168 173 176  186 158 148 134 138
Sunday 194  202 186  166 181  118 144
Monday 218 198 196 251  146 194 174 129 160
Tuesday  177 176  121 155 165 169 118 137
Wednesday 250 187   231 171 170 143 123 150
Thursday 214 187 186   183 157 162 145 134
Avg. mg/dL 198 186 195 193 189 168 169 158 128 143
y = 0.1427x + 148.51
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Figure 9. Line graph comparison of lab values with line equation to show change in 
slope and notation of confounding factors of study.  
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CHAPTER 5 
DISCUSSION 
Study results show changes in all measures that all warrant discussion.  This case 
study investigates the effects of blood donation combined with chromium 
supplementation to improve blood glucose levels measured by HbA1c levels and insulin 
sensitivity measured by HOMA score.  Complications during the study extended study 
time to twenty weeks, weakened interpretation of the data, and created confounding 
variables for the protocol. 
 During visit number one when colleting blood for hematocrit levels the finger was 
milked, squeezed to induce bleeding, which caused a false low hematocrit due to excess 
serum in the sample.  As a result of this error our subject was initially excluded from the 
study which resulted in the study being extended to 20 weeks instead of 19 as proposed.  
The hematocrit was properly measured the following week and participant was included 
pending lab results from the baseline venous blood draw.  Hematocrit levels were 
measured first to avoid unnecessary venous blood draws if this measure excluded the 
participant.  Subject was included in study after review of all labs at visit two, and first 
blood donation was scheduled. 
 Visit 3 results shows a reduction of baseline HbA1c from 7.5% to 7.3% after the 
first blood donation which may be related to the decrease in iron and ferritin levels as 
expected.  This finding is weakened due to a change in medication; however, all iron 
markers show a response to the blood donations which has been previously supported by 
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a study by Karlijn Peffer and colleagues as discussed (Peffer et al., 2013).  In addition C-
reactive protein levels increased which also increase ferritin levels.  Despite an increase 
in C-reactive protein, ferritin and iron concentrations are still lower than baseline at visit 
3.  Additionally, ferritin levels were highest at baseline when CRP was at its lowest 
concentrations during the study duration.  This suggests that blood donations are effective 
in lowering ferritin and iron despite elevated CRP concentrations.  The lowering of 
ferritin and iron show a correlation with a lower HbA1c at visit 3.  A decrease in iron 
levels has been associated to lower blood glucose levels which support the possibility of 
the blood donation contributing to the improved HbA1c score (Hansen et al., 2014).  The 
addition of Januvia was before baseline data was collected which further supports the 
possibility of the blood donations contributing to a reduction in HbA1c. 
The HOMA score increased from 20.4 to 42.8 based on an increased fasting 
insulin level of 59 uIU/mL  to 81 uIU/mL and fasting blood glucose levels on the day of 
the blood draws of 140 mg/dL at baseline and 214 mg/dL on the morning of visit three.  
It is important to note that the purpose of the blood donation is to improve insulin 
production by decreasing ROS in the pancreas, and to reduce competitive binding to 
allow chromium the bind for transportation into cell.  The blood donations accomplished 
this based on the reduction of % saturation from 21% to 17% from baseline to after the 
first blood donation, and the increase in TIBC.  The HOMA score is a measure of insulin 
sensitivity as measured by the relationship to beta cell insulin production and fasting 
plasma glucose. 
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This finding is complicated by the addition of Januvia which helps the body to 
produce more insulin, and on the day of the blood draw the fasting glucose was not 
measured by subject until after 8:00 am.  Subject began taking Januvia which is an oral 
medication that increases the body’s insulin production (WHITLEY, 2007).  Increase of 
the HOMA score supports the overall theory that iron depletion alone is not sufficient to 
improve insulin production and sensitivity.  Results show an increase in fasting insulin 
with an excess of fasting plasma glucose on the day of the blood draw resulting in the 
highest HOMA score of the study.  This may suggest poor insulin action which is 
hypothesized to be improved with chromium supplementation. 
 Visit 4 is after the second blood donation and shows an increase in HbA1c from 
baseline from 7.5% to 7.6% which conflicts with iron markers.  Iron levels continue to 
decrease from baseline of 57 µg /dL to 51 µg /dL and ferritin from 212 ng/mL to 89 
ng/mL which should correlate to a decrease in blood glucose levels.  Although C-reactive 
protein is decreased form visit 3 it is still elevated from baseline which is known to 
increase ferritin levels.  It is clear that blood donation continues to improve iron markers, 
however, significant confounding factors before visit 4 makes data interpretation 
unreasonable. 
Subject is a student and his normal routine was interrupted by a winter school 
break and a Christmas holiday.  Daily fasting blood glucose readings decreased and many 
of the readings were taken after 8 a.m. which suggests readings not taken upon waking 
and or irregular sleep patterns.  The findings are further complicated due to another 
change in medication.  First subject stopped taking Januvia and let the medication clear 
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his system so he could begin Glipizide, which helps the pancreas produce more insulin, 
so effect of decreased iron on insulin production and sensitivity cannot be interpreted 
(Go, Kyriakidou-Himonas, & Berelowitz, 2004).  Next, due to a prescription error the 
subject went without all medications for week 13.  Finally, once the prescription was 
corrected the subject resumed Metformin with the addition of a new medication, 
Glipizide.  The HOMA score for visit 4 shows a decrease from visit 3 and an increase 
from baseline.  This score along with the HbA1c concentrations cannot be properly 
interpreted due to the irregular daily fasting glucose levels and confounding variables 
described prior to visit 4. 
At visit 5 all medication has been stable for 7 weeks; however, Januvia has been 
replaced with Glipizide which is different than baseline.  Glipizide works primarily by 
increasing pancreatic beta cell production of insulin and secondarily by increasing 
glucose usage and decreasing the production of glucose by the liver (Go et al., 2004).  
This complicates the interpretation of HbA1c concentrations along with the subject 
presenting to visit 5 with an active case of bronchitis which may have contributed to the 
elevated CRP and ferritin levels and the time period of less than ninety days on the new 
medication may impair an accurate HbA1c reading.  The combination of these factors 
makes interpretation of HbA1c levels unreasonable. 
Chromium results show an increased concentration from baseline from .2 to .7.  
This is remarkable as it correlates to a decrease in HOMA score from baseline from 20.4 
to 12.2 at final visit.  The combination of iron depletion and chromium supplementation 
suggests a decrease in insulin resistance based on the HOMA score.  This is further 
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supported by research from C. Derrick Quarles and colleagues that suggests once 
chromium binds Tf, it is transported into the cell and binds chromodulin which increases 
kinase activity and lowers insulin in the blood (Quarles Jr et al., 2011).  The lowest 
fasting insulin levels and HOMA score of the study are seen when the chromium 
concentrations have been increased from baseline at .2 to .7 at visit 5 which is more than 
a threefold increase.  The iron concentrations and percent saturation has consistently 
declined regardless of any confounding factors discussed throughout the study duration 
while the TIBC consistently increased.  This further supports the theory that once iron 
levels are decreased the capacity for chromium to bind Tf increases and allows chromium 
to enter the cell and become biologically active as chromodulin (Albarracin, Fuqua, 
Evans, & Goldfine, 2008).   
Overall, confounding factors weaken the findings based on medication changes, 
fluctuations in daily and seasonal lifestyle, and illnesses that arise.  This is the life of a 
diabetic and was to be expected during the course of this twenty week study.  This case 
study cannot be generalized to the general public and serves as an exploration for the 
feasibility of combining blood donations to reduce iron and chromium supplementation 
to improve glucose management and insulin sensitivity.  Results from this study suggest 
that this protocol should be tested in a larger population. 
Strengths of this study are the combined therapies that have not been tested and 
suggest feasibility of larger study.  The study design is strong with a modification to 
extend the chromium supplementation time to six to eight weeks.  This would be a better 
time frame as diabetics change medication dosages and types to manage glucose levels 
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and this time frame would give a better measure of chromium affect.  Limitations of this 
study are recruitment and fluctuations in non-insulin medications. 
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CHAPTER 6 
CONCLUSION 
 This twenty week case study showed feasibility of further testing in a larger study 
of this combined protocol of iron depletion through blood donation and chromium 
supplementation.  Our results do not show promise for our first hypothesis of Phlebotomy 
and chromium treatments will improve glucose management as indicated by daily fasting 
glucose measurement and HbA1c levels in individuals with T2D based on confounding 
factors.  
 Our results show promise for the second hypothesis of Phlebotomy and chromium 
treatments will improve insulin sensitivity as measured by HOMA in individuals with 
T2D. 
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